

Resource Summary Report

Generated by [RRID](#) on Sep 2, 2026

TOV-112D

RRID:CVCL_3612

Type: Cell Line

Proper Citation

RRID:CVCL_3612

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3612

Proper Citation: RRID:CVCL_3612

Description: Cell line TOV-112D is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ovarian endometrioid adenocarcinoma

Defining Citation: [PMID:10949993](#), [PMID:11641787](#), [PMID:16380993](#), [PMID:18507860](#), [PMID:19058220](#), [PMID:19288585](#), [PMID:20204287](#), [PMID:22328975](#), [PMID:22460905](#), [PMID:22710073](#), [PMID:22931248](#), [PMID:24023729](#), [PMID:25230021](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27235858](#), [PMID:27397505](#), [PMID:27561551](#), [PMID:28196595](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:33328126](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: OCCP ovarian cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: TOV-112D

Synonyms: TOV-112d, TOV112D, TOV-112, TOV112

Cross References: BTO:BTO_0005182, CLO:CLO_0009384, EFO:EFO_0005263, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-3593, ATCC:CRL-11731, BCRC:60408, BioGRID_ORCS_Cell_line:201,

BioSample:SAMN03471348, BioSample:SAMN10988342, cancercellines:CVCL_3612, CancerTools:161766, Cell_Model_Passport:SIDM01170, ChEMBL-Cells:ChEMBL3707165, ChEMBL-Targets:ChEMBL3707166, Cosmic:875292, Cosmic:1066219, Cosmic:1102818, Cosmic:1113278, Cosmic:1139220, Cosmic:1305335, Cosmic:1709264, Cosmic:2186587, Cosmic-CLP:1299070, DepMap:ACH-000048, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1299070, GEO:GSE35972, GEO:GSM274697, GEO:GSM289383, GEO:GSM289384, GEO:GSM289387, GEO:GSM289388, GEO:GSM313690, GEO:GSM659407, GEO:GSM711721, GEO:GSM784575, GEO:GSM851944, GEO:GSM887710, GEO:GSM888803, GEO:GSM1001425, GEO:GSM1001426, GEO:GSM1001489, GEO:GSM1291152, GEO:GSM1340594, GEO:GSM1341134, GEO:GSM1374964, GEO:GSM1670546, IARC_TP53:20197, LiGeA:CCLE_580, LINCS_LDP:LCL-1920, PharmacDB:TOV112D_1604_2019, PRIDE:PXD003668, PRIDE:PXD030304, Progenetix:CVCL_3612, PubChem_Cell_line:CVCL_3612, Wikidata:Q54972795

ID: CVCL_3612

Record Creation Time: 20220427T221632+0000

Record Last Update: 20260830T000126+0000

Ratings and Alerts

No rating or validation information has been found for TOV-112D.

No alerts have been found for TOV-112D.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Tong J, et al. (2026) p53 and fatty acids collaborate to trigger ferroptosis via the FBXO2-FABP5 axis in colorectal cancer. *Redox biology*, 90, 104043.

Yang L, et al. (2026) Trichostatin Analogues From the Karst Cave Associated *Streptomyces* sp. DX6D14. *Chemistry & biodiversity*, 23(5), e71334.

Jorgensen A, et al. (2026) Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. *Advanced biology*, 10(3), e00404.

Min Y, et al. (2026) The USP19-DnaJC7 Axis Stabilizes p53 in Cisplatin-Treated Epithelial Ovarian Cancer. *Cells*, 15(10).

Kimmel GJ, et al. (2026) Universal principles of cell population growth follow from local contact inhibition. *iScience*, 29(6), 115953.

Wang M, et al. (2025) Serum-derived exomiR-188-3p is a promising novel biomarker for early-stage ovarian cancer. *Open medicine (Warsaw, Poland)*, 20(1), 20251266.

Wang K, et al. (2025) Molecular mechanisms of CAND2 in regulating SCF ubiquitin ligases. *Nature communications*, 16(1), 1998.

limori Y, et al. (2025) SLFN11-mediated tRNA regulation induces cell death by disrupting proteostasis in response to DNA-damaging agents. *Nucleic acids research*, 53(15).

Sasaki M, et al. (2025) Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. *Cancer research communications*, 5(1), 24.

limori Y, et al. (2025) SLFN11-mediated tRNA regulation induces cell death by disrupting proteostasis in response to DNA-damaging agents. *bioRxiv : the preprint server for biology*.

Onji H, et al. (2024) Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks. *Oncogene*, 43(32), 2475.

Kofink C, et al. (2022) A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo. *Nature communications*, 13(1), 5969.

Yamamoto TM, et al. (2022) Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors. *Molecular cancer therapeutics*, 21(4), 647.

Altintas DM, et al. (2022) The PSI Domain of the MET Oncogene Encodes a Functional Disulfide Isomerase Essential for the Maturation of the Receptor Precursor. *International journal of molecular sciences*, 23(20).

Faucher-Giguère L, et al. (2022) High-grade ovarian cancer associated H/ACA snoRNAs promote cancer cell proliferation and survival. *NAR cancer*, 4(1), zcab050.

Cumin C, et al. (2022) Glycosphingolipids are mediators of cancer plasticity through independent signaling pathways. *Cell reports*, 40(7), 111181.

Li Y, et al. (2021) Down-regulation of PSMD4 can attenuate autophagy, enhance the accumulation of intracellular ROS, and increase the sensitivity of epithelial ovarian cancer to carboplatin by inhibiting the NF- κ B pathway. *Translational cancer research*, 10(11), 4756.

Dorrigiv D, et al. (2021) Microdissected Tissue vs Tissue Slices-A Comparative Study of Tumor Explant Models Cultured On-Chip and Off-Chip. *Cancers*, 13(16).

Karnezis AN, et al. (2021) Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines. *Gynecologic oncology*, 160(2), 568.

Huang YL, et al. (2020) Collagen-rich omentum is a premetastatic niche for integrin α 2-mediated peritoneal metastasis. *eLife*, 9.